Moderna's 3-month data raise hopes for COVID-19 vaccine durability

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 4, 2020 at 11:33 AM.

  1. #1 cafead, Dec 4, 2020 at 11:33 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Antibody levels stayed elevated in the 90 days after people received the second dose of Moderna’s COVID-19 vaccine, raising hopes that the prophylactic can provide protection for one year.

    With Moderna and Pfizer, in partnership with BioNTech, showing mRNA vaccines provide protection against symptomatic COVID-19 in the short term, attention has turned to durability. The full picture of the durability of protection will only become clear over time, but immunogenicity data from the phase 1/2 trial of Moderna’s mRNA-1273 offer encouragement.

    article source
     
    Quote

Reply to Thread